期刊文献+

吲哚菁绿联合亚甲蓝在乳腺癌前哨淋巴结活组织检查中的应用价值 被引量:18

Indocyanine green combined with methylene blue for sentinel lymph node biopsy in breast cancer patients
原文传递
导出
摘要 目的探讨吲哚菁绿联合亚甲蓝在乳腺癌前哨淋巴结活组织检查(SLNB)中的应用价值。方法根据纳入、排除标准,选取2015年5-12月在第三军医大学西南医院乳腺外科住院行术前检查提示腋窝淋巴结阴性的104例乳腺癌患者进行前瞻性研究。按照随机数字表法将患者分成2组(每组均为52例),分别采用吲哚菁绿联合亚甲蓝(试验组)或者核素联合亚甲蓝(对照组)作为淋巴示踪剂对患者进行SLNB,术中根据冰冻检查结果决定是否行腋窝淋巴结清扫。比较两种方法在乳腺癌SLNB中检出率的差别。偏态分布的计量资料用M(P25-P75)表示。两组患者间前哨淋巴结(SLN)和转移性SLN检出率及检出数目的比较,采用χ-2检验、Fisher确切概率检验或非参数检验。结果试验组52例患者中,皮肤淋巴管荧光显影者49例(94.2%,49/52),SLN荧光显影者52例(100%,52/52),SLN检出率为100%(52/52),而对照组的检出率为96.2%(50/52)。试验组转移性SLN检出率为32.7%(17/52),明显高于对照组的15.4%(8/52)(χ-2=4.27,P=0.039)。试验组共检出SLN190枚,中位数为3(2-4)枚,对照组共检出SLN 158枚,中位数为2(1-4)枚,两组患者SLN检出数目相似(Z=-1.58,P=0.113)。试验组共检出转移性SLN 26枚,中位数为0(0-1)枚,而对照组共检出转移性SLN 9枚,中位数为0(0-0)枚,两组相比,差异有统计学意义(Z=-2.15,P=0.032)。结论在乳腺癌SLNB术中应用吲哚菁绿联合亚甲蓝法示踪,其SLN检出率与核素联合亚甲蓝双标法相当,且能提高转移性SLN的检出率,并可协助术者精准定位SLN的位置,降低手术难度,具有较高的临床应用价值。 Objective To evaluate the application value of indocyanine green(ICG)combined with methylene blue(MB)for sentinel lymph node biopsy(SLNB)in breast cancer patients. Methods Totally 104 breast cancer patients with axillary node negative indicated by preoperative examination in Department of Breast Surgery,Southwest Hospital,Third Military Medical University,from May 2015 to December 2015 were enrolled for a prospective study. They were randomly divided into two groups(n = 52)by the random number table method:experimental group with MB combined with ICG as lymph tracer,control group with nuclide combined with MB as lymph tracer for SLNB. During operation,the surgeon decided whether to perform axillary lymph node dissection according to the result of intraoperative frozen section examination. The detection rates in SLNB were compared between two groups. Skewed distribution data were described as M(P25-P75). χ-2test and Fisher's exact probability test or non-parametric test were used to compare the number of detected sentinel lymph nodes(SLNs)and metastatic SLNs,and the detection rates of the two in two groups. Results In 52 patients of experimental group,subcutaneous lymphatic vesselsc were visualized in 49 patients(94. 2%,49 /52)and SLNs were visualized in 52(100%). The detection rate of SLNs was 100%(52 / 52)in experimental group,96. 2%(50 / 52) in control group. The detection rate of metastatic SLNs was 32. 7%(17 / 52) in experimental group,significantly higher than 15. 4%(8 / 52)in control group(χ-2= 4. 27,P = 0. 039). Totally190 SLNs [median 3(2-4)] were detected in experimental group,158 [median 2(1-4)] in control group,indicating no significant difference(Z =- 1. 58,P = 0. 113). Twenty-six metastatic SLNs [median 0(0- 1)]were detected in experimental group,Nine[median 0(0-0)]in control group,indicating significant difference(Z=- 2. 15,P = 0. 032). Conclusion Compared with nuclide plus methylene blue,indocyanine green combined with methylene blue for intraoperative SLNB in breast cancer patients has similar detection rate of SLNs and higher detection rate of metastatic SLNs,with the advantages of precise positioning of SLNs,reducing the difficulty of operation,worthy of clinical application.
出处 《中华乳腺病杂志(电子版)》 CAS CSCD 2016年第2期87-91,共5页 Chinese Journal of Breast Disease(Electronic Edition)
关键词 乳腺肿瘤 前哨淋巴结活组织检查 吲哚花青绿 Breast neoplasms Sentinel lymph node biopsy Indocyanine green
  • 相关文献

参考文献17

  • 1Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial I J]. J Clin Oncol, 2005, 23 (19): 4312-4321.
  • 2Benson JR. An alternative to initial axillary-lymph-node dissection [J]. Lancet Oncol, 2010, 11(10) : 908-909.
  • 3Goyal A, Newcombe RG, Chhabra A, et al. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer--results of the ALMANAC validation phase [ J ]. Breast CancerRes Treat, 2006, 99 (2) : 203 -208.
  • 4Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase 11I trial [ J ]. Lancet Oncol, 2007, 8(10): 881-888.
  • 5Zavaguo G, De Salvo GL, Sealco G, et al. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial [ J]. Ann Surg, 2008, 247(2) : 207-213.
  • 6Strayer ME, Meijnen P, van Tienhoven G, et al. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial[J]. Ann Surg Oneol, 2010, 17(7) : 1854-1861.
  • 7Leong SP, Shen ZZ, Liu TJ, et al. Is breast cancer the same disease in Asian and Western countries? [J]. World J Surg, 2010, 34(10): 2308-2324.
  • 8Cox CE, Salud CJ, Cantor A, et al. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis [ J ]. J Am Con Surg, 2001, 193(6) : 593--600.
  • 9Ahmed M, Purushotham AD, Douek M. Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review [ J ]. Lancet Oncol, 2014, 15(8) : e351-e362.
  • 10Niebling MG, Pleijhuis RG, Bastiaannet E, et al. A systematic review and meta-analysos of sentinel lymph node identification in breast cancer and melanoma, a plea for tracer mapping[J]. Eur J Surg Oncol, 2016, 42(4) : 466-473.

同被引文献102

引证文献18

二级引证文献95

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部